English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Overall survival of patients with hepatocellular carcinoma ( HCC ) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination ( PPV ) for  HCC , in which the peptides were selected from 31 peptide candidates based on the pre‐existing immunity. Twenty‐six  HCC  patients refractory to locoregional therapies (cohort 1) and 30 patients refractory to both locoregional and systemic therapies (cohort 2) were entered into the study. There were no severe adverse events related to  PPV  except for one injection site reaction. At the end of the first cycle of six vaccinations, successful  CTL  or IgG boosting was observed in 57% or 46% of patients in cohort 1 and in 54% or 52% of patients in cohort 2, respectively. Successful IgG boosting at the end of the second cycle was observed in the majority of patients tested. Median overall survival was 18.7 months (95% confidence interval, 12.2–22.5 months) in cohort 1, and 8.5 months (95% confidence interval, 5.9–12.2 months) in cohort 2. Based on the higher rates of immune boosting and the safety profile of  PPV , further clinical studies of  PPV  would be warranted for patients with  HCC  refractory to not only locoregional therapy but also both locoregional and systemic therapies. The protocol of this study was registered with the  UMIN  Clinical Trials Registry ( UMIN 1882 and  UMIN 3590).

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies